Transfusion after coronary artery bypass surgery: The impact of heparin-bonded circuits

European Journal of Cardio-thoracic Surgery

Volumn 16, Issue 2, 1999, Pages 206-210

  Mahoney, Chris Brown ^a   Lemole, Gerald M ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

Blood transfusion; Cardiopulmonary bypass; Clinical outcomes; Heparin bonded circuit

Indexed keywords

CEFAZOLIN; HEPARIN; PROTAMINE; VANCOMYCIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD TRANSFUSION; BODY SURFACE; CARDIOPULMONARY BYPASS; CATHETERIZATION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ERYTHROCYTE CONCENTRATE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY BYPASS; ERYTHROCYTE TRANSFUSION; FEMALE; HEPARIN; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; ODDS RATIO; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0032765340     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(99)00157-8     Document Type: Article

References (23)

1. Stump D.A., Rogers A.T., Hammon J.W., Newman S.P. Cerebral emboli and cognitive outcome after cardiac surgery. J Cardiothorac Vas Anes. 10:(1):1996;113-119.
2. Yasnoff W.A., Page U.S. Effective use of outcomes data in cardiovascular surgery. SPIE Proc. 2307:1994;212-222.
3. Jones E.L., Weintraub W.S., Craver J.M., Guyton R.A., Cohen C.L. Coronary bypass surgery. Is the operation different today? J Thorac Cardiovasc Surg. 101:1991;108-115.
4. Aldea G., O'Gara P., Shapira O.M., Treanor P., Osman A., Patalis E., et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg. 65:1998;425-433.
5. Fosse E., Moen E., Johnson E., et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 58:1994;472-477.
6. Gorman R., Ziats N., Gikakis N., Edmunds H., et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 111:1996;1-12.
7. Gu Y., van Oeveran W., Akkerman C., et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 55:1993;917-922.
8. Jansen P., TeVelthuis H., Huybregts R., et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin coated circuits. J Thorac Cardiovasc Surg. 110:1995;829-834.
9. Ovrum E., Mollnes T., Fosse E., et al. High and low heparin dose with heparin-coated cardiopulmonary bypass circuits: activation of complement and granulocytes. Ann Thorac Surg. 60:1995;1755-1761.
10. Pekna M., Hagman L., Halden E., et al. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg. 58:1994;421-424.
11. Gibbon J. Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med. 37:1954;171-185.
12. Gravlee G., Davis R., Utley J. Cardiopulmonary bypass: principles and practice. 1993;Williams and Wilkins, Baltimore.
13. Kirklin J., Westaby S., Blackstone E., et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 86:1983;845-857.
14. Von Segessor L., Weiss B., Pasic M., et al. Risk and benefits of low systemic heparinization during open-heart operations. Ann Thorac Surg. 58:1994;391-398.
15. Redmond J.M., Gillinov A.V., Stuart R.S., et al. Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg. 56:1993;474-479.
16. Gu Y., van Oeveren W., van der Kamp K., Akkerman C., Boonstra P., Wildevuur R. Heparin-coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion. 6:1991;221-225.
17. Aldea G., Doursounian P., O'Gara P., et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg. 62:1996;410-418.
18. Wendel H., Heller W., Hoffmeister H. Pathway of platelet protection in heparin-coated devices and its significance for cardiac surgery. Trans Soc Biomat. 21:1995;28.
19. Ferraris V.A., Berry W.R., Klingman R.R. Comparison of blood reinfusion techniques used during coronary artery bypass grafting. Ann Thorac Surg. 56:1993;433-440.
20. Mahoney C.B. Heparin bonded circuits: clinical outcomes and costs. Perfusion. 13:1998;219-232.
21. Ovrum E., Brosstad F., Am Holen E, et al. E. Effect on coagulation and fibrinolysis with reduced vs. full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation. 92:1995;2579-2584.
22. Svenmarker S., Sandstrom E., Karlsson T., Jansson E., Haggmark S., Lindholm R., Appelblad M., Aberg T. Clinical effects of the heparin coated surface in cardiopulmonary bypass. Eur J Cardiothorac Surg. 11:1997;957-964.
23. Aldea G., Shemin R., Heparin-bonded circuits improve clinical outcomes in patients undergoing CABG: a new 'gold standard'? ACC Current J Rev. (March/April):1998;45-48.